Human amniotic epithelial cells (hAEC) isolated from term placenta have stem cell-like properties, differentiate into tissue specific cells and reduce lung and liver inflammation and fibrosis following transplantation into disease models established in mice. These features together with their low immunogenicity and immunosuppressive properties make hAEC an attractive source of cells for potential therapeutic applications. However, generation of large cell numbers required for therapies through serial expansion in xenobiotic-free media may be a limiting factor. We investigated if hAEC could be expanded in xenobiotic-free media and if expansion altered their differentiation capacity, immunophenotype, immunosuppressive properties and production of immunomodulatory factors. Serial expansion in xenobiotic-free media was limited with cumulative cell numbers and population doubling times significantly lower than controls maintained in fetal calf serum. The epithelial morphology of primary hAEC changed into mesenchymal-stromal like cells by passage 4–5 (P4–P5) with down regulation of epithelial markers CK7, CD49f, EpCAM and E-cadherin and elevation of mesenchymal-stromal markers CD44, CD105, CD146 and vimentin. The P5 hAEC expanded in xenobiotic-free medium differentiated into osteocyte and alveolar epithelium-like cells, but not chondrocyte, hepatocyte, α- and β-pancreatic-like cells. Expression of HLA Class IA, Class II and co-stimulatory molecules CD80, CD86 and CD40 remained unaltered. The P5 hAEC suppressed mitogen stimulated T cell proliferation, but were less suppressive compared with primary hAEC at higher splenocyte ratios. Primary and P5 hAEC did not secrete the immunosuppressive factors IL-10 and HGF, whereas TGF-β1 and HLA-G were reduced and IL-6 elevated in P5 hAEC. These findings suggest that primary and expanded hAEC may be suitable for different cellular therapeutic applications.
References
[1]
Ilancheran S, Moodley Y, Manuelpillai U (2009) Human fetal membranes: a source of stem cells for tissue regeneration and repair? Placenta 30: 2–10.
[2]
Ilancheran S, Michalska A, Peh G, Wallace EM, Pera M, et al. (2007) Stem cells derived from human fetal membranes display multilineage differentiation potential. Biol Reprod 77: 577–588.
Bilic G, Zeisberger SM, Mallik AS, Zimmermann R, Zisch AH (2008) Comparative characterization of cultured human term amnion epithelial and mesenchymal stromal cells for application in cell therapy. Cell Transplant 17: 955–968.
[5]
Stadler G, Hennerbichler S, Lindenmair A, Peterbauer A, Hofer K, et al. (2008) Phenotypic shift of human amniotic epithelial cells in culture is associated with reduced osteogenic differentiation in vitro. Cytotherapy 10: 743–752.
[6]
Moodley Y, Ilancheran S, Samuel C, Vaghjiani V, Atienza D, et al. (2010) Human amnion epithelial cell transplantation abrogates lung fibrosis and augments repair. Am J Respir Crit Care Med 182: 643–651.
[7]
Meng XT, Li C, Dong ZY, Liu JM, Li W, et al. (2008) Co-transplantation of bFGF-expressing amniotic epithelial cells and neural stem cells promotes functional recovery in spinal cord-injured rats. Cell Biol Int 32: 1546–1558.
[8]
Sankar V, Muthusamy R (2003) Role of human amniotic epithelial cell transplantation in spinal cord injury repair research. Neuroscience 118: 11–17.
[9]
Wei JP, Zhang TS, Kawa S, Aizawa T, Ota M, et al. (2003) Human amnion-isolated cells normalize blood glucose in streptozotocin-induced diabetic mice. Cell Transplant 12: 545–552.
[10]
Cargnoni A, Gibelli L, Tosini A, Signoroni PB, Nassuato C, et al. (2009) Transplantation of allogeneic and xenogeneic placenta-derived cells reduces bleomycin-induced lung fibrosis. Cell Transplant 18: 405–422.
[11]
Manuelpillai U, Tchongue J, Lourensz D, Vaghjiani V, Samuel CS, et al. (2010) Transplantation of human amnion epithelial cells reduces hepatic fibrosis in immunocompetent CCl4 treated mice. Cell Transplant 19: 1157–1168.
[12]
Yeager AM, Singer HS, Buck JR, Matalon R, Brennan S, et al. (1985) A therapeutic trial of amniotic epithelial cell implantation in patients with lysosomal storage diseases. Am J Med Genet 22: 347–355.
[13]
Banas RA, Trumpower C, Bentlejewski C, Marshall V, Sing G, et al. (2008) Immunogenicity and immunomodulatory effects of amnion-derived multipotent progenitor cells. Hum Immunol 69: 321–328.
[14]
Wolbank S, Peterbauer A, Fahrner M, Hennerbichler S, van Griensven M, et al. (2007) Dose-dependent immunomodulatory effect of human stem cells from amniotic membrane: a comparison with human mesenchymal stem cells from adipose tissue. Tissue Eng 13: 1173–1183.
[15]
Li H, Niederkorn JY, Neelam S, Mayhew E, Word RA, et al. (2005) Immunosuppressive factors secreted by human amniotic epithelial cells. Invest Ophthalmol Vis Sci 46: 900–907.
[16]
Toda A, Okabe M, Yoshida T, Nikaido T (2007) The potential of amniotic membrane/amnion-derived cells for regeneration of various tissues. J Pharmacol Sci 105: 215–228.
[17]
Felka T, Schafer R, De Zwart P, Aicher WK (2010) Animal serum-free expansion and differentiation of human mesenchymal stromal cells. Cytotherapy 12: 143–153.
[18]
Gargett CE, Schwab KE, Zillwood RM, Nguyen HP, Wu D (2009) Isolation and culture of epithelial progenitors and mesenchymal stem cells from human endometrium. Biol Reprod 80: 1136–1145.
[19]
Pera MF, Reubinoff B, Trounson A (2000) Human embryonic stem cells. J Cell Sci 113(Pt 1): 5–10.
[20]
Chan J, Ban EJ, Chun KH, Wang S, McQualter J, et al. (2008) Methylprednisolone induces reversible clinical and pathological remission and loss of lymphocyte reactivity to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis. Autoimmunity 41: 405–413.
[21]
Kollar K, Cook MM, Atkinson K, Brooke G (2009) Molecular mechanisms involved in mesenchymal stem cell migration to the site of acute myocardial infarction. Int J Cell Biol 2009: 1–8.
[22]
Terada S, Matsuura K, Enosawa S, Miki M, Hoshika A, et al. (2000) Inducing proliferation of human amniotic epithelial (HAE) cells for cell therapy. Cell Transplant 9: 701–704.
[23]
Siddappa R, Licht R, van Blitterswijk C, de Boer J (2007) Donor variation and loss of multipotency during in vitro expansion of human mesenchymal stem cells for bone tissue engineering. J Orthop Res 25: 1029–1041.
[24]
Ochsenbein-Kolble N, Bilic G, Hall H, Huch R, Zimmermann R (2003) Inducing proliferation of human amnion epithelial and mesenchymal cells for prospective engineering of membrane repair. J Perinat Med 31: 287–294.
[25]
Yang H, Xia Y, Lu SQ, Soong TW, Feng ZW (2008) Basic fibroblast growth factor-induced neuronal differentiation of mouse bone marrow stromal cells requires FGFR-1, MAPK/ERK, and transcription factor AP-1. J Biol Chem 283: 5287–5295.
[26]
Doucet C, Ernou I, Zhang Y, Llense JR, Begot L, et al. (2005) Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol 205: 228–236.
[27]
Bernardo ME, Avanzini MA, Perotti C, Cometa AM, Moretta A, et al. (2007) Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: further insights in the search for a fetal calf serum substitute. J Cell Physiol 211: 121–130.
[28]
Ullmann U, In't Veld P, Gilles C, Sermon K, De Rycke M, et al. (2007) Epithelial-mesenchymal transition process in human embryonic stem cells cultured in feeder-free conditions. Mol Hum Reprod 13: 21–32.
[29]
Zavadil J, Bottinger EP (2005) TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 24: 5764–5774.
[30]
Willis BC, Liebler JM, Luby-Phelps K, Nicholson AG, Crandall ED, et al. (2005) Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 166: 1321–1332.
[31]
Korpal M, Kang Y (2008) The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol 5: 115–119.
[32]
Thiery JP (2003) Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15: 740–746.
[33]
Ahmed N, Maines-Bandiera S, Quinn MA, Unger WG, Dedhar S, et al. (2006) Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium. Am J Physiol Cell Physiol 290: C1532–1542.
[34]
Ackland ML, Newgreen DF, Fridman M, Waltham MC, Arvanitis A, et al. (2003) Epidermal growth factor-induced epithelio-mesenchymal transition in human breast carcinoma cells. Lab Invest 83: 435–448.
[35]
Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442–454.
[36]
Vacanti V, Kong E, Suzuki G, Sato K, Canty JM, et al. (2005) Phenotypic changes of adult porcine mesenchymal stem cells induced by prolonged passaging in culture. J Cell Physiol 205: 194–201.
[37]
Banfi A, Bianchi G, Notaro R, Luzzatto L, Cancedda R, et al. (2002) Replicative aging and gene expression in long-term cultures of human bone marrow stromal cells. Tissue Eng 8: 901–910.
[38]
Djouad F, Charbonnier LM, Bouffi C, Louis-Plence P, Bony C, et al. (2007) Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 25: 2025–2032.
[39]
Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, et al. (2002) Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99: 3838–3843.
[40]
Nasef A, Mathieu N, Chapel A, Frick J, Francois S, et al. (2007) Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 84: 231–237.
[41]
Bahri R, Hirsch F, Josse A, Rouas-Freiss N, Bidere N, et al. (2006) Soluble HLA-G inhibits cell cycle progression in human alloreactive T lymphocytes. J Immunol 176: 1331–1339.
[42]
Tamagawa T, Ishiwata I, Sato K, Nakamura Y (2009) Induced in vitro differentiation of pancreatic-like cells from human amnion-derived fibroblast-like cells. Hum Cell 22: 55–63.
[43]
Peister A, Mellad JA, Larson BL, Hall BM, Gibson LF, et al. (2004) Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood 103: 1662–1668.
